<DOC>
	<DOC>NCT01299077</DOC>
	<brief_summary>The purpose of this study is to observe the overall satisfaction of patients with degenerative disc disease after receiving triple therapy.</brief_summary>
	<brief_title>Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China</brief_title>
	<detailed_description>DDD (lumbar disc degenerative disease ) patients who have been prescribed triple therapy (MBL+ MYO+ NSAIDs) over 2 weeks of triple therapy were enrolled in the study. They were asked to assess their overall satisfaction degree on triple therapy.</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Inclusion criteria: 1. lumbar degenerative disc disease (DDD) 2. patients who have been prescribed over 2 weeks of triple therapy Exclusion criteria: Patients who do not meet inclusion criteria for DDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Lumbar disc degenerative disease</keyword>
	<keyword>Methycobal</keyword>
</DOC>